

Special Lecture

Saturday, June 30th, 2018 9 : 10~9 : 40 Room 1 (2F Niho BC)

Chair : Seigo Kitano
(President, Oita University)

Kozo Akino
(Member of the house of councillors)

Invited Lecture 1

Friday, June 29th, 2018 11 : 50~12 : 30 Room 1 (2F Niho BC)

Chair : Kentaro Sugano
(Dept of Medicine Jichi Medical University)

***H. pylori* infection: selected areas of interest and clinical challenges in 2018**

Peter Malfertheiner

(Clinic of Gastroenterology, Hepatology and Infectious Diseases Otto von Guericke University,
Magdeburg, Germany)

Invited Lecture 2

Saturday, June 30th, 2018 11 : 50~12 : 30 Room 1 (2F Niho BC)

Chair : Masahiro Asaka
(President, Health Sciences University of Hokkaido)

Improving success and reliability of *H. pylori* therapy while avoiding antibiotic misuse.

David Y. Graham

(Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of
Medicine, Houston, TX USA)

Uehara *H. pylori* Best Presentation Award

Friday, June 29th, 2018 13:40~14:10 Room 1 (2F Niho BC)

Chair : Nobuhiro Sakaki
(Foundation for Detection of Early Gastric Carcinoma)

***H. pylori* infection causes autophagy impairment by DNA methylation, promoting gastric carcinogenesis**

Sohachi Nanjo

(Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)

Academic Award (Basic Research)

Friday, June 29th, 2018 14:20~14:35 Room 1 (2F Niho BC)

Chair : Shigeru Kamiya
(Department of Infectious Diseases, Kyorin University School of Medicine)

Mechanisms to develop diseases by *H. pylori* and anthropological research using *H. pylori*

Yoshio Yamaoka

(Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine)

Academic Award (Clinical Research)

Friday, June 29th, 2018 14:35~14:50 Room 1 (2F Niho BC)

Chair : Toshio Fujioka
((Medical Corporation Shinseikai) Takada Chuo Hospital)

Gastric mucosal pathogenesis by *Helicobacter pylori* infection and the development of its eradication therapy

Hidekazu Suzuki

(Fellowship Training Center and Medical Education Center, Keio University School of Medicine, Tokyo, JAPAN)

Joint Panel Discussion by JSHR and JGCA

Friday, June 29th, 2018 10:30~11:50 Room 1 (2F Niho BC)

The Road to Decrease of Gastric Cancer Death in Japan

Chair : Yasuhiro Kodera

(President of Japanese Gastric Cancer Association / Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine)

Toshiro Sugiyama

(President of Japanese Society for *Helicobacter* Research / Dept of Cancer Prevention and Therapeutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)

Population-Based Screening for Gastric Cancer

Katsuaki Kato

(Cancer Detection Center, Miyagi Cancer Society)

H. pylori eradication

Hidekazu Suzuki

(Medical Education Center, Keio University School of Medicine)

Surgery

Takeshi Sano

(Gastroenterological Center, Cancer Institute Hospital)

ESD

Hiroyuki Ono

(Shizuoka Cancer Center)

Educational Lecture

Sunday, July 1st, 2018 10:00~11:00 HorutoHall OITA (3F Main Conference Room)

Chair : Kengo Tokunaga

(Department of General Medicine, Kyorin University School of Medicine)

Commentator : Akiko Shiotani

(Division of Gastroenterology Department of Internal Medicine Kawasaki Medical School)

Basic aspects and diagnosis of *Helicobacter pylori* infection

Shotaro Nakamura

(Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University)

The therapies for *Helicobacter pylori* infection and the prevention of gastric cancer

Tadayoshi Okimoto

(Department of Gastroenterology, Faculty of Medicine, Oita University, Japan)

Morning Seminar

Saturday, June 30th, 2018 8:30~9:00 Room 1 (2F Niho BC)

Chair : Shinichi Takahashi
(Dept. of Internal Medicine, Gastroenterology, Kosei Hospital)

Co-sponsored : FUJIFILM Medical Co., Ltd.

Endoscopic diagnosis of early gastric cancer associated with *H.pylori* infection using laser endoscope

Hiroyuki Imaeda
(Dept. of Gastroenterology, Saitama Medical University)

Luncheon Seminar 1

Friday, June 29th, 2018 12:40~13:30 Room 1 (2F Niho BC)

Chair : Shin Maeda
(Yokohama City University Graduate School of Medicine Department of Gastroenterology)

Co-sponsored : Otsuka Pharmaceutical Co., Ltd. / Takeda Pharmaceutical Co., Ltd.

Artificial intelligence diagnosis of *Helicobacter pylori* Infection Based on Endoscopic Images

Tomohiro Tada
(AI Medical Service Inc. / Tada Tomohiro Institute of Gastroenterology and Proctology)

Kyoto Classification of Gastritis and Spectrum of Gastric cancer

Tomoari Kamada
(Kawasaki medical school)

Luncheon Seminar 2

Friday, June 29th, 2018 12:40~13:30 Room 2 (2F Niho A)

Chair : Masanori Ito
(Department of Gastroenterology and Metabolism, HIROSHIMA UNIVERSITY HOSPITAL)

Co-sponsored : DENKA SEIKEN CO., LTD. / FUJIFILM Wako Pure Chemical Corporation

New era of *Helicobacter pylori* serological diagnosis with LATEX method - Comparative evaluation of 6 *Helicobacter pylori* diagnosis kits -

Nobuo Aoyama
(Aoyama Clinic: GI Endoscopy & IBD Center)

Luncheon Seminar 3

Friday, June 29th, 2018 12:40~13:30 Room 3 (3F Seto)

Chair : Kazuma Fujimoto
(Department of Internal Medicine Saga Medical School)

Co-sponsored : AstraZeneca K.K. / Daiichi Sankyo Co., Ltd.

Ideal acid suppression therapy in post *H.pylori* era

Akihito Nagahara
(Department of Gastroenterology, Juntendo University School of Medicine)

Luncheon Seminar 4

Saturday, June 30th, 2018 12:40~13:30 Room 1 (2F Niho BC)

Chair : Hidekazu Suzuki
(Medical Education Center, Keio University School of Medicine)
Co-sponsored : Astellas Pharma Inc. / Zeria Pharmaceutical Co., Ltd.

Treatment strategy for functional dyspepsia including post-eradication of *H.pylori*
Mototsugu Kato
(National Hospital Organization Hakodate Hospital)

Luncheon Seminar 5

Saturday, June 30th, 2018 12:40~13:30 Room 2 (2F Niho A)

Chair : Motoyasu Kusano
(Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital)
Co-sponsored : Otsuka Pharmaceutical Co., Ltd.

By which age should elderly people be done eradication of *Helicobacter pylori*?
-Improvement level of endoscopic findings after eradication by age and the study of
Histological changes-
Junzo Uchiyama
(Nanmouri Medical Clinic)

Meaning of *H.pylori* eradication therapy to elderly people.
Katsuhiro Mabe
(National Hospital Organization Hakodate Hospital)

Luncheon Seminar 6

Saturday, June 30th, 2018 12:40~13:30 Room 3 (3F Seto)

Chair : Naomi Uemura
(Kohnodai Hospital, National Center for Global Health and Medicine)
Co-sponsored : EA Pharma Co., Ltd.

Drug-drug interactions that should be noted during *H.pylori* eradication therapy.
Takahisa Furuta
(Center for Clinical Research, Hamamatsu University School of Medicine)

Symposium 1

Friday, June 29th, 2018 8:30~10:30 Room 1 (2F Niho BC)

Long term follow-up after *Helicobacter pylori* eradication

Chair : Akiko Shiotani
(Division of Gastroenterology Department of Internal Medicine Kawasaki Medical School)

Shotaro Nakamura
(Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University)

Commentator : Toshifumi Ohkusa
(Department of Microbiota Research, Juntendo University Graduate School of Medicine)

- S1-01** (Keynote) **Characteristics of gastric cancer discovered after eradication therapy and its accurate diagnosis**
Masanori Ito
(Department of Gastroenterology and Metabolism, Hiroshima University Hospital)
- S1-02** **Clinicopathological analysis of gastric mucosa before eradication *H.pylori* predicts gastric cancers.**
Norihiro Ashihara
(Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine)
- S1-03** **Investigation of gastric cancer risk after *Helicobacter pylori* eradication**
Momoko Tsuda
(Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine)
- S1-04** **Clinical and endoscopic features of gastric cancers discovered after *H. pylori* eradication**
Kunihiko Sato
(Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University)
- S1-05** **Exosomal miRNA in gastric cancer after eradication therapy**
Kyosuke Goda
(Division of Gastroenterology Department of Internal Medicine, Kawasaki Medical School)
- S1-06** **Problems in long-term follow-up of gastric MALT lymphoma**
Hiroko Nebiki
(Department of Gastroenterology, Osaka City General Hospital)
- S1-07** **Long-term prognosis after the *Helicobacter pylori* eradication therapy for gastric MALT lymphoma**
Yuichi Matsuno
(Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University)
- S1-08** **Anti-*Helicobacter pylori* therapy for gastric MALT lymphoma: Real world data from a prospective multicenter study**
Ichiro Oda
(Endoscopy Division, National Cancer Center Hospital)

- S1-09 High-dose clarithromycin monotherapy for *H. pylori*-negative/-eradicated MALT lymphomas: a preliminary report**
 Shotaro Nakamura
 (Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University School of Medicine)
- S1-10 Link between *Helicobacter pylori* eradication and lipid metabolism**
 Hiroyuki Nagashima
 (Department of Gastroenterology, Rumoi City Hospital / Department of Gastroenterology, Hokkaido Cancer Center)
- S1-11 Effects of *H. pylori* Eradication on Reflux Symptom, Obesity, and Metabolic Syndrome: a Yamagata Cohort Study**
 Yu Sasaki
 (Department of Gastroenterology, Faculty of Medicine, Yamagata University / Division of Endoscopy, Yamagata University Hospital / Department of Advanced Cancer Science, Faculty of Medicine, Yamagata University)
- S1-12 The study of risk factors for reflux esophagitis development by *H.pylori* eradication therapy**
 Yoshida Yuichiro
 (Division of Gastroenterology, Matsuyama Red Cross Hospital)
- S1-13 Risk of Barrett's adenocarcinoma after eradication of *H. pylori*; prospective endoscopic evaluation**
 Susumu Take
 (Department of Internal Medicine, Fukuwatari Municipal Hospital / Department of Gastroenterology, Nippon Kokan Fukuyama Hospital)
- S1-14 Eradication therapy for *H.pylori* improves nutrition status in hemodialysis patients with protein-energy wasting**
 Mitsushige Sugimoto
 (Division of Digestive Endoscopy, Shiga University of Medical Science Hospital)

Symposium 2

Friday, June 29th, 2018 10 : 30~11 : 50 Room 2 (2F Niho A)

New development of basic research for *H. pylori*

Chair : Yoshio Yamaoka
 (Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine)
 Takako Osaki
 (Department of Infectious Diseases, Kyorin University School of Medicine)

- S2-01 Enhanced risk of gastric carcinogenesis in *H. pylori*-infected gastric mucosa by resident flora-derived butyrate**
 Hitoshi Tsugawa
 (Department of Biochemistry, Keio University School of Medicine)
- S2-02 Gut microbiota in children with *Helicobacter pylori***
 Toshihiko Kakiuchi
 (Department of Pediatrics, Faculty of Medicine, Saga University)

- S2-03** Two dimensional human gastric organoid model of *Helicobacter pylori* infection including virulence factor
Takahiro Uotani
(Department of Gastroenterology and Hepatology, Michael DeBakey Veterans Affairs Medical Center and Baylor College of Medicine / Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine)
- S2-04** Analysis of persistent infection mechanism of *Helicobacter pylori* using hyper-mutator strain
Hitomi Mimuro
(Department of Infectious Diseases, Research Institute for Microbial Diseases, Osaka University / Division of Bacteriology, Institute of Medical Science, The University of Tokyo)
- S2-05** Biological diversity on *Helicobacter pylori* between host NY43 strain and its prophage (KHP30)-cured derivative
Hiroaki Takeuchi
(Department of Clinical Laboratory Medicine, Kochi Medical School, Kochi University)
- S2-06** Identification of genes involved in massive biofilm formation by *Helicobacter pylori* strain TKI402
Hideo Yonezawa
(Department of Infectious Diseases, Kyorin University School of Medicine)
- S2-07** Genetic alterations of a *H. pylori* isolate from a patient with gastric cancer
Yoshiyuki Watanabe
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine / Department of Internal Medicine, Kawasaki Rinko General Hospital)
- S2-08** Decoding genome and methylome of hundreds of *H. pylori* strains
Ichizo Kobayashi
(Faculty of Medicine, Kyorin University / University of Paris-Saclay)
- S2-09** Serum concentrations of *H. pylori* virulence factors (*vacA*, *cagA*) and their relation with serum cytokines
Ichiro Imoto
(Digestive Endoscopy Center, Doshinkai Tohyama Hospital)

Panel Discussion 1

Friday, June 29th, 2018 8:30~10:30 Room 2 (2F Niho A)

Endoscopic diagnosis of *H. pylori*-uninfected and post-eradicated gastric cancer in *H. pylori* negative era.

Chair : Takashi Kawai
(Department of Gastroenterological Endoscopy, Tokyo Medical University)
Tomoari Kamada
(Department of Health Care Medicine, Kawasaki Medical School General Medical Center)

- PD1-01** **Clinicopathological characteristics of gastric cancer without *Helicobacter pylori* infection.**
(Keynote 1)
Daisuke Yoshimura
(Division of Gastroenterology, Saiseikai Fukuoka General Hospital)
- PD1-02** **The characteristic endoscopic images of *H. pylori*-uninfected early gastric cancers**
Masami Tanaka
(Department of Gastroenterology, Toranomon Hospital)
- PD1-03** **Clinicopathological analysis of gastric cancer found in cases with autoimmune gastritis**
Shiho Suzuki
(Department of Gastroenterology, Kakogawa Central City Hospital)
- PD1-04** **Clinicopathological features of gastric cancer in patients with autoimmune gastritis**
Hiroki Yaita
(Division of Gastroenterology, Matsuyama Red Cross Hospital)
- PD1-05** ***H.pylori* infection is the important risk factor for the gastric cancer in autoimmune gastritis**
Yasuhiko Maruyama
(Department of Gastroenterology, Fujieda Municipal General Hospital)
- PD1-06** **Endoscopic diagnosis for early gastric cancers after *Helicobacter pylori* eradication**
(Keynote 2)
Masaaki Kobayashi
(Division of Gastroenterology, Niigata Cancer Center Hospital)
- PD1-07** **Study of evaluation in diagnosis of early gastric cancer after *H.pylori* eradication using transnasal endoscopy**
Kyosuke Yanagisawa
(Department of Gastroenterological Endoscopy, Tokyo Medical University)
- PD1-08** **Newly surface irregularity of the post-eradicated gastric mucosa makes difficult to detect the gastric carcinoma.**
Takuji Yamasaki
(Division of Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, School of Medicine, The Jikei University)
- PD1-09** **Pathological and endoscopic characteristics of non neoplastic epithelium after *Helicobacter pylori* eradication.**
Keiko Yamamoto
(Division of endoscopy, Hokkaido University Hospital)

PD1-10 *H. pylori* eradication increases the prevalence of differentiated type gastric cancer with submucosal invasion.

Kosaku Hata

(Department of Gastroenterology and Metabolism, Hiroshima University Hospital)

PD1-11 Characteristics of gastric cancer after *Helicobacter pylori* eradication and EBV-associated gastric carcinoma.

Ryo Ogawa

(Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine)

Panel Discussion 2

Friday, June 29th, 2018 14 : 50~17 : 20 Room 2 (2F Niho A)

Current and Future strategies of diagnosis of *Helicobacter pylori*

Chair : Masanori Ito

(Department of Gastroenterology and Metabolism, Hiroshima University)

Masaaki Kodama

(Faculty of Welfare and Health Science, Oita University)

PD2-01 Gastrin as a serum biomarker of *Helicobacter pylori* gastritis

Hiroshi Kishikawa

(Department of Gastroenterology, Ichikawa General Hospital, Tokyo Dental College)

PD2-02 *Helicobacter pylori* serum antibody by latex method with the reference to fecal antigen and endoscopic findings

Hideo Suzuki

(Tsukuba Preventive Medicine Research Center, Tsukuba University Hospital /

Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba)

PD2-03 Evaluation of the anti-*H. pylori* IgG antibodies using latex immunoassay

Daisuke Chinda

(Department of Gastroenterology and Hematology, Graduate School of Medicine, Hirosaki University)

PD2-04 Validity of default cut-off values of serum *H. pylori* antibodies for diagnosing *H. pylori* infection

Hiroyuki Sakae

(Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

PD2-05 Usefulness of novel anti-*H. pylori* antibody detection kit using a latex turbidimetric immunoassay.

Kensuke Fukuda

(Department of Gastroenterology, Faculty of Medicine, Oita University)

PD2-06 Evaluation of 6 *H. pylori* serological diagnosis kits among strictly diagnosed infectious status

Nobuo Aoyama

(Aoyama Clinic, GI Endoscopy and IBD)

- PD2-07** Evaluation when the antibody titer is 3 U/mL or more and less than 10 U/mL using the LZ test Eiken
Masahiko Ohtaka
(Yamanashi Koseiren Health Care Center)
- PD2-08** Diagnostic accuracy of latex agglutination turbidimetric immunoassay in adolescents for *H. pylori* infection
Koshiro Tsutsumi
(Department of Gastroenterology, Faculty of Medicine, Oita University / Department of Gastroenterology, Yuri Kumiai General Hospital)
- PD2-09** The significance to diagnosis *H.pylori* infection by measuring the serum antibody younger than 40years old.
Shinji Nasu
(Department of Gastroenterology, Inobe Hospital)
- PD2-10** Serum anti-*H. pylori* antibody titers measured by E-plate and LZ test in subjects with successful eradication.
Satoru Nakagawa
(Mutsu General Hospital)
- PD2-11** A prospective study about the precision of three serum *H.pylori* antibodies
Kazuhiko Inoue
(Junpukai Health Maintenance Center)
- PD2-12** Disagreement between Testmate and ImmunoCard in the assessment of eradication therapy
Kuniaki Miyazawa
(Department of Gastroenterology, Tugaru general hospital)
- PD2-13** Efficacy receiving proton pump inhibitor / H2 receptor antagonist therapy for histologically identifying *H. pylori*
Takahiro Horii
(Horii Clinic)
- PD2-14** Association study of serum anti-*H. pylori* antibody titer to endoscopic findings, pathology, and urea breath test
Osamu Toyoshima
(Gastroenterology, Toyoshima Endoscopy Clinic)
- PD2-15** Utility of Kyoto classification of gastritis in high-negative *H. pylori* antibody subjects of medical check-up
Koji Otani
(Department of Premier Preventive Medicine, Osaka City University Graduate School of Medicine)
- PD2-16** Hybrid-ABC *H. pylori* infection diagnosis, a combination of serum and endoscopic ABC classifications
Masayuki Inui
(Inui Clinic of Internal Medicine)
- PD2-17** Kyoto gastritis classification and ABC test for diagnosis of *H. pylori* in gastric cancer screening
Ryosuke Hirai
(Department of Gastroenterology, Kurashiki Central Hospital)

PD2-18 Can capsule endoscopy stratify the gastric cancer risk?

Ko Miura
(Department of Internal medicine, Tuyama Chuo Hospital)

PD2-19 Study on *H.pylori* infection diagnosis method by gastric X-ray examination

Mitsugi Yasuda
(Ningen Dock Center, KKR Takamatsu Hospital)

Panel Discussion 3

Saturday, June 30th, 2018 9:50~11:50 Room 1 (2F Niho BC)

Strategies for treating *Helicobacter pylori* against young people for prevention of gastric cancer

Chair : Masumi Okuda
(Dep of Pediatrics, Aichi Medical University)
Katsuhiro Mabe
(Dep of Gastroenterology, National Hospital Organization Hakodate hospital)

PD3-01 *H. pylori* screening and eradication for junior high school students - Result for 5 years

in Maniwa City -
Hidenori Kondo
(Kondo Hospital)

PD3-02 Epidemiology Evaluation and Vonoprazan's Effect and Safety in *H. pylori* Screening and Treat

Toshihiko Kakiuchi
(Department of Pediatrics, Faculty of Medicine, Saga University)

PD3-03 Current status of *H. pylori* screening for junior high school students in Hakodate city

Mototsugu Kato
(Department of Gastroenterology, National Hospital Organization Hakodate Hospital)

PD3-04 Introduction of screening for *H. pylori* infection in routine school medical examination -final report-

Koichi Sato
(Department of Gastroenterology, Shinshu University School of Medicine)

PD3-05 *H. pylori* screening and treatment for college student ~3,000 scale program collaborating with local government~

Soichiro Sue
(Department of Gastroenterology, Yokohama City University Graduate School of Medicine)

PD3-06 Current situation and problems of countermeasures against *H.pylori* in middle and high school students in Hokkaido

Katsuhiro Mabe
(Department of Gastroenterology, National Hospital Organization Hakodate Hospital)

PD3-07 *Helicobacter pylori* test for new adults at a coming-of-age ceremony in Iijima Town, Nagano prefecture

Horiuchi Akira
(Digestive Disease Center, Showa Inan General Hospital)

- PD3-08** *H. pylori* Eradication Registry for Junior and Senior High School Students by JSHR
HPERCJSHS JSHR
(Department of Public Health, Aichi Medical University)
- PD3-09** Gastric cancer and *Helicobacter pylori* in children and adolescents in Japan
Masumi Okuda
(Department of Pediatrics, Aichi Medical University School of Medicine / Department of
General Medicine and Community Health Science, Hyogo College of Medicine)
- PD3-10** Change in urine *H. pylori* antibody titer during 2-year-interval in junior high school
students
Ryosuke Miyamoto
(Department of Pediatrics, Aichi Medical University)

Workshop 1

Friday, June 29th, 2018 15 : 50~17 : 20 Room 3 (3F Seto)

Current knowledge of gastric non-*H. pylori Helicobacter* infection in Japan

Chair : Masahiko Nakamura

(School of Pharmacy, Kitasato University)

Tadashi Shimoyama

(Gastroenterology, Hirosaki University Graduate School of Medicine)

- WS1-01** 6 cases of *Helicobacter heilmannii* like organisms (HHLO) infection in Aomori prefecture since 1993
Tadashi Shimoyama
(Gastroenterology, Hirosaki University Graduate School of Medicine)
- WS1-02** Evaluation of *Helicobacter Heilmannii* Like Organism in Ibaraki prefecture
Junichi Iwamoto
(Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center)
- WS1-03** Prevalence and clinicopathologic characteristics of 21 patients with gastric disease infected with gastric NHPH
Toshihisa Tsukadaira
(Department of Internal medicine, Kenwakai Hospital)
- WS1-04** Analysis of diagnosis and clinical condition of gastric non-*Helicobacter pylori*-*Helicobacter* infection
Yasuhiro Tamura
(Department of Gastroenterology, Aichi Medical University School of Medicine)
- WS1-05** Analysis of 4 cases with non-*Helicobacter pylori Helicobacter*-infected gastritis
Shiho Suzuki
(Department of Gastroenterology, Kakogawa Central City Hospital)
- WS1-06** Investigation of HHLO infection, and gastric microbiota in gastric MALT lymphoma
Kengo Tokunaga
(Department of General Medicine, Kyorin University School of Medicine)
- WS1-07** Development of methods for the rapid detection of *Helicobacter suis* infection
Hidenori Matsui
(Shirokane Campus, Kitasato University)

Workshop 2

Saturday, June 30th, 2018 9:50~11:50 Room 2 (2F Niho A)

The good and bad sides of *H.pylori* eradication therapy in super-elderly patients

Chair : Kengo Tokunaga

(Department of General Medicine, Kyorin University School of Medicine)

Mitsushige Sugimoto

(Division of Digestive Endoscopy, Shiga University of Medical Science Hospital)

Commentator : Daizo Saito

(NIHONBASHI DAIZO CLINIC)

WS2-01 Current status of first and second *Helicobacter pylori* eradication therapy in metropolitan area

Hideki Mori

(Department of Gastroenterology, National Hospital Organization Tokyo Medical Center / Tokyo *Helicobacter pylori* study group)

WS2-02 Current status and result of *H.pylori* eradication in elderly patients

Shinichi Mukai

(Department of Gastroenterology, Hiroshima City Asa Citizens Hospital / Department of Endoscopy, Hiroshima City Asa Citizens Hospital)

WS2-03 Eradication ratio and adverse events incidence in aged patients' *H. pylori* eradication therapy

Takuma Kagami

(Hamamatsu University School of Medicine)

WS2-04 Effect of *Helicobacter pylori* eradication for elder patients

Yuichi Waragai

(Department of Internal Medicine and Gastroenterology, Japanese Red Cross Fukushima Hospital)

WS2-05 Consideration of the frequency of side effects by *H.pylori* infection treatment for elderly people

Satoshi Kobayashi

(Department of Gastroenterology, HOKUSHIN GENERAL HOSPITAL Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare)

WS2-06 *H. pylori* eradication improves dyspepsia-related symptoms on elderly cases

Murata Masaki

(Department of Gastroenterology, Shiga University of Medical Science)

WS2-07 Evaluation of upper abdominal symptoms after *Helicobacter pylori* eradication in elderly people.

Shoko Ono

(Department of Gastroenterology, Hokkaido University Hospital)

WS2-08 Is it the age or the environment factor? Which is more strongly associated to the development gastritis of *H.pylori* ?

Junzo Uchiyama

(Nanmouri Medical Clinic Anti-Aging / Comprehensive Medical Checkup Center)

Workshop 3

Saturday, June 30th, 2018 15:00~17:30 Room 1 (2F Niho BC)

For the improvement of eradication rates of *H. pylori*

Chair : Takahisa Furuta
(Center for Clinical Research, Hamamatsu University School of Medicine)
Osamu Handa
(Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)

- WS3-01** Status of the *Helicobacter pylori* eradication therapy at our hospital
Kumiko Ueda
(Department of Gastroenterology, Juntendo University School of Medicine)
- WS3-02** RCT of Vonoprazan and Rabeprazole in the second-line triple therapy for *Helicobacter pylori* infection
Kohei Matsumoto
(Department of Gastroenterology, Juntendo University)
- WS3-03** Comparison of vonoprazan and rabeprazole in 2nd-line *H.pylori* eradication therapy
Takafumi Fuchino
(Arita Gastro-Intestinal Hospital)
- WS3-04** Tailor-made therapy using vonoprazan improves the eradication rate in first-line eradication of *H.pylori*
Tetsuya Shimmura
(Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)
- WS3-05** Treatment strategy of *Helicobacter Pylori* infection
Takashi Jin
(Department of internal medicine, Shibetsu general hospital / Department of Gastroenterology, Tonan hospital)
- WS3-06** A study on *H. pylori* first-line eradication therapy using vonoprazan and drug susceptibility test at our hospital
Hiroyuki Nishibayashi
(Department of Gastroenterology and Hepatology, Kawanishi Municipal Hospital, Hyogo)
- WS3-07** Improvement of eradication therapy with antibiotics-sensitivity test in difficult cases.
Shigemi Nakajima
(Department of Medicine, JCHO Shiga Hospital / Consortium for Community Medicine, Shiga University of Medical Science)
- WS3-08** Molecular testing for antimicrobial resistance to clarithromycin of *Helicobacter pylori* using stool sample
Toshihiko Kakiuchi
(Department of Pediatrics, Faculty of Medicine, Saga University)
- WS3-09** Detection of CAM-resistance of *H. pylori* by PCR with gastric juice in vonoprazan-based eradication
Mihoko Yamade
(First Department of Medicine, Hamamatsu University School of Medicine)

- WS3-10** Efficacy of optimal dosing scheme for AMPC and adequate gastric acid suppression on *H. pylori* eradication therapy.
Naohito Shirai
(Department of Gastroenterology, Enshu Hospital)
- WS3-11** High Dose Cam Is Better On Vonoprazan (P-CAB) Plus Amx With Cam Based *H.Pylori* Eradication Triple Therapy Regimen.
Takuji Yamasaki
(Division of Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, School of Medicine, The Jikei University)
- WS3-12** Influence of *Clostridium butyricum* as probiotics on *Helicobacter pylori* eradication.
Yuji Shimada
(Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital)
- WS3-13** Evaluation of background factors affecting success rate of first-line triple therapy.
Hiroyuki Tamaki
(Department of Gastroenterology, Takamatsu Red Cross Hospital)
- WS3-14** RCT of Vonoprazan/AMPC/STFX and PPI/AMPC/STFX in third-line treatment of *H. pylori*
Soichiro Sue
(Department of Gastroenterology, Yokohama City University Graduate School of Medicine)
- WS3-15** Efficacy of low dose rifabutin including regimen as a third-line or fourth-line *H. pylori* eradication
Tatsuto Mizuno
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)
- WS3-16** Monotherapy of a novel intervenolin derivative, AS-1934, is an effective treatment for *H. pylori* infection
Tomokazu Ohishi
(Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation)

Poster Session 1

Saturday, June 30th, 2018 13 : 40~14 : 05 Poster Session (2F Kuju)

Diagnostic Endoscopy

Chair : Akira Horiuchi
(Showa Inan General Hospital Digestive Disease Center)

- P01-01** A case of acute gastric mucosal lesion by *Helicobacter pylori* infection
Narihiro Shibukawa
(Department of Gastroenterology, NTT West Osaka Hospital)
- P01-02** The relationship between *H.pylori* infection and Kyoto classification for the chronic gastritis
Longxue Jin
(Department of Surgery, Yokohama Asahi Chuo General Hospital)
- P01-03** A study of 2 cases of eosinophilic esophagitis who were newly diagnosed after *H.pylori* eradication therapy.
Takashi Chiba
(Miyagi Cancer Society)
- P01-04** A case in which HP infection was observed only in esophageal esophageal inlet patch
Masahide Kita
(Department of Gastroenterology, Okayama City Hospital, Okayama, Japan)

Poster Session 2

Saturday, June 30th, 2018 14 : 05~14 : 30 Poster Session (2F Kuju)

H. pylori Infection in Children

Chair : Chieko Kato
(Department of Gastroenterology and Hematology Graduate School of Medicine, University of Toyama)

- P02-01** Association between *H.pylori* infection and delivery route
Takuji Gotoda
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)
- P02-02** Proposal of preventing *Helicobacter pylori* infection in children by cutting off its infection route.
Kazuaki Kawada
(Shizuoka Red Cross Hospital Medical check-up center, Transnasal endoscopy center)
- P02-03** The changes in gastric mucosal lesions after *H. pylori* eradication therapy in children.
Nobuyasu Arai
(Department of Pediatrics, Juntendo University Faculty of Medicine)
- P02-04** Evaluation of eradication therapy in 49 children with symptomatic *Helicobacter pylori* infection
Tomoko Takano
(Department of Pediatrics, Osaka General Medical Center)

Poster Session 3

Saturday, June 30th, 2018 13:40~14:05 Poster Session (2F Kuju)

Ulcer

Chair : Kazuhide Higuchi
(2nd Department of Internal Medicine Osaka Medical College)

- P03-01** How does *H.pylori* infection plays a role in bleeding gastric ulcer?
Yoko Kubosawa
(Department of Gastroenterology, National Hospital Organization, Tokyo Medical Center)
- P03-02** Efficacy of *Helicobacter Pylori* eradication therapy immediately after endoscopic submucosal dissection
Toshihisa Takeuchi
(Endoscopy Center, Osaka Medical College Hospital)
- P03-03** Factors affecting scar formation of artificial ulcer after endoscopic submucosal dissection for gastric tumor
Hiromitsu Ban
(Division of Digestive Endoscopy, Shiga University of Medical Science /
Department of Gastroenterology, Kusatsu General Hospital)
- P03-04** The efficacy of P-CAB to healing of post gastric ESD ulcer compared with those of PPI
Tetsuro Yoshimura
(Department of Gastroenterology, Aomori city hospital)

Poster Session 4

Saturday, June 30th, 2018 14:05~14:30 Poster Session (2F Kuju)

Clinical Aspects

Chair : Ken Ohnita
(Inoue Hospital)

- P04-01** Association of *Helicobacter pylori* infection and lower serum hemoglobin levels among Japanese general population
Hiroko Nakagawa
(Department of Public Health, Nagoya City University Graduate School of Medical Sciences)
- P04-02** The effect of *H.pylori* eradication therapy on the nutritional health of dialysis patients
Atsushi Majima
(Department of Gastroenterology and Hepatology, Omihachiman Community Medical Center)
- P04-03** The associations between hemodialysis and prevalence of *H. pylori* and gastroduodenal lesions
Yasuyuki Goto
(Department of Gastroenterology, Nagoya Kyoritsu Hospital)
- P04-04** Association between anti-parietal cell antibody and *H.pylori* infection
Satoshi Takeshita
(Department of General Medicine and Emergency Care, Toho University)

Poster Session 5

Saturday, June 30th, 2018 13 : 40~14 : 05 Poster Session (2F Kuju)

Gastric Cancer 1

Chair : Ken Haruma
(General Internal Medicine 2, General Medical Center, Kawasaki Medical School)

P05-01 Characteristic of *Helicobacter pylori* Uninfected or Eradicated Gastric Cancer

Ken Ohnita
(Department of Gastroenterology and Hepatology, Nagasaki University Hospital /
Department of Gastroenterology and Hepatology, Inoue Hospital)

P05-02 Clinical characteristics and endoscopic findings in gastric adenocarcinoma of fundic gland-type

Taketo Otsuka
(Division of Digestive Endoscopy, Shiga University of Medical Science)

P05-03 Clinicopathological characteristics of *H. pylori*-negative gastric cancer experienced in our department

Yuji Abe
(Department of Gastroenterology, Oita Red Cross Hospital)

P05-04 A case of *Helicobacter pylori*-uninfected early poorly-differentiated adenocarcinoma of the stomach

Hiromi Nakajima
(Fuchu Hospital)

Poster Session 6

Saturday, June 30th, 2018 14 : 05~14 : 30 Poster Session (2F Kuju)

Gastric Cancer 2

Chair : Hiroyuki Okada
(Department of Gastroenterology and Hepatology Okayama University
Graduate School)

P06-01 A case of advanced gastric cancer diagnosed 18 months after eradication of *Helicobacter pylori* for nodular gastritis

Tohru Kotera
(Department of Medical Examination, Uji-Tokushukai Medical Center)

P06-02 Rate of surveillance, clinical features of patients with gastric tumors after eradication of *Helicobacter pylori*

Tomohiro Iwai
(Department of Gastroenterology, Toyokawa City Hospital)

P06-03 A study for change of atrophy between 2005 and 2015 in gastric cancer patients

Masaru Mizutani
(Department of Gastroenterology, Tokyo metropolitan cancer detection center)

P06-04 A case of advanced gastric cancer detected 10 years after *H. pylori* eradication

Takafumi Fuchino
(Arita Gastro-Intestinal Hospital)

Poster Session 7

Saturday, June 30th, 2018 14:10~14:30 Poster Session (2F Kuju)

Gastric Cancer 3

Chair : Hiroyoshi Ota
(Shinshu University, Clinical laboratory Sciences)

- P07-01** Fractal dimension of the surface of early gastric cancer
Fumiya Komatsu
(Department of General Medicine and Emergency Care, Toho University)
- P07-02** Analysis of surgically resected cases of gastric carcinoma after eradication of *H. pylori* at our institution
Atom Katayama
(Department of Surgery, Mitaka Chuo Hospital)
- P07-03** The effect of oxidative stress for pathogenesis of gastric cancer among patients with inactive gastritis
Yoshiyasu Kono
(Department of Gastroenterology, Okayama University Hospital)

Poster Session 8

Saturday, June 30th, 2018 13:40~14:05 Poster Session (2F Kuju)

Health Check 1

Chair : Takeshi Matsuhisa
(Department of Gastroenterology, Tama-Nagayama University Hospital, Nippon Medical School)

- P08-01** *H. pylori* antibody test and upper GI screening using the mobile vehicle with transnasal endoscopy.
Satoshi Ikeda
(Ikeda hospital)
- P08-02** *Helicobacter pylori* screening examination for the twenties and thirties
Hiromi Nishiarai
(Medical Examination Center, Seikei-kai Chiba Medical Center)
- P08-03** Current status of serum *Helicobacter pylori* antibody test in our facility
Kyoko Ito
(Shimbashi Medical Check-up Center, Department of Preventive Medicine, The Jikei University School of Medicine)
- P08-04** Estimation of the degree of gastric mucosal atrophy based on serum pepsinogen after eradication *H.pylori*.
Takahiro Suzuki
(First department of medicine, Hamamatsu University School of Medicine)

Poster Session 9

Saturday, June 30th, 2018 14 : 05~14 : 30 Poster Session (2F Kuju)

Health Check 2

Chair : Shogo Kikuchi
(Department of Public Health, Aichi Medical University, School of Medicine)

- P09-01 Pepsinogen levels of young people for ABC classification**
Yuka Obayashi
(Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine)
- P09-02 Gastric cancer risk stratification conducted as screening for citizens of Yokosuka City: 5-year summary**
Yasuhiro Mizuno
(Ma-ru Clinic Yokosuka)
- P09-03 Current situation of ABC method in our health screening**
Shohei Uraoka
(Division of Gastroenterology, Matsuyama Red Cross Hospital)
- P09-04 ABC screening utilizing regular health checks of hospital staff (compared to five years ago)**
Kenji Amagai
(Department of Gastroenterology, Ibaraki Prefectural Central Hospital and Regional Cancer Center)

Poster Session 10

Saturday, June 30th, 2018 13 : 40~14 : 00 Poster Session (2F Kuju)

Bacteriology and Pathology 1

Chair : Intetsu Kobayashi
(Dept. of Infection Control and Prevention Faculty of Nursing, Toho University)

- P10-01 Influence of infection of *Helicobacter pylori* on gut microbiota**
Chikara Iino
(Department of Gastroenterology, Hirosaki University Graduate School of Medicine /
Department of Gastroenterology, Hirosaki National Hospital)
- P10-02 Enrichment of *H. pylori* mutant strains after eradication therapy analyzed by gastric wash-based pyrosequencing**
Ritsuko Oikawa
(Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine)
- P10-03 A case of coccoid-form *H. pylori* infection diagnosed after treatment with vonoprazan.**
Yuki Tsubakimoto
(Department of Medicine, JCHO Shiga Hospital)

Poster Session 11

Saturday, June 30th, 2018 14:10~14:30 Poster Session (2F Kuju)

Bacteriology and Pathology 2

Chair : Takuji Yamasaki

(The Jikei University School of Medicine Department of Internal Medicine,
Division of Gastroenterology and Hepatology.)

- P11-01** Survival of *Helicobacter pylori* in environmental soil and sterilized soil
Fuhito Hojo
(Institute of Laboratory Animals, Graduate School of Medicine, Kyorin University)
- P11-02** The characteristics of pseudopyloric metaplasia and the effects of eradication therapy for *H.pylori* on it
Yasuhiro Wada
(Department of Gastroenterology, Faculty of Medicine, Oita University /
Department of Pathological Diagnostics, Faculty of Medicine, Shiga University of Medical Science)
- P11-03** Examination of histopathological features of sticky mucus
Shotaro Inoue
(Department of Gastroenterology, Oita Red Cross Hospital)

Poster Session 12

Saturday, June 30th, 2018 13:40~14:10 Poster Session (2F Kuju)

Diagnosis and Examination of Infection

Chair : Kiichi Satoh

(Department of Gastroenterology International University of Health and
Welfare Hospital)

- P12-01** Accuracy of UBT and a stool antigen test after *H. pylori* eradication therapy with vonoprazan.
Toshihisa Tsukadaira
(Department of Internal medicine, Kenwakai Hospital)
- P12-02** Diagnostic accuracy of rapid urine antibody test for detection of *H.Pylori* among children
Chika Kusano
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)
- P12-03** Comparative analysis of serum *H. pylori* antibody in 7 Asian countries using latex aggregation turbidity assay
Junko Akada
(Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University)
- P12-04** Evaluation of a new EIA kits for the measurement of serum anti-*H. pylori* IgG antibodies
Shiro Hayamizu
(Hirosaki University, Graduate School of Medicine, Gastroenterology and Hematology)
- P12-05** Effect of Acotiamide Hydrochloride Hydrate on the ¹³C-Urea Breath Test in *H. pylori* positive patients
Kazuhiro Mizukami
(Department of Gastroenterology, Faculty of Medicine, Oita University)

Poster Session 13

Saturday, June 30th, 2018 13 : 40~14 : 10 Poster Session (2F Kuju)

Eradication Therapy 1

Chair : Mitsuru Kaise
(Department of Gastroenterology and Liver Internal Medicine Nippon medical school)

- P13-01** A case of *H.pylori* infection with decreased drug susceptibility after the first-line eradication therapy.
Reiko Kyodo
(Department of Pediatrics Juntendo University Faculty of Medicine)
- P13-02** Investigation of Eradication rates, Side effects and Hemorrhagic Colitis after Second-Line Therapy
Mitsunori Maeda
(Department of Gastroenterology, Utunomiya National Hospital /
Department of Gastroenterology, Dokkyo Medical University)
- P13-03** Study of the effectiveness of *Helicobacter pylori* eradication using vonoprazan in our hospital
Yoshitaka Yamaguchi
(Ikeda City Hospital)
- P13-04** Examination of rate of primary *H. pylori* eradication in the cases with side effect ~ Vonoprazan vs PPI ~
Hiroyoshi Endo
(Department of Internal Medicine, Saiseikai Karatsu Hospital)
- P13-05** A study for effectiveness of Vonoprazan on 3rd and 4th line eradication therapy of *Helicobacter pylori*
Moeka Sato
(Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy)

Poster Session 14

Saturday, June 30th, 2018 14 : 05~14 : 30 Poster Session (2F Kuju)

Eradication Therapy 2

Chair : Makoto Sasaki
(Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)

- P14-01** Comparison of the triple and quadruple therapies on *Helicobacter pylori* infected
Tetsufumi Uchida
(Department of Gastroenterology, Faculty of Medicine, Tokai University)
- P14-02** Current status of *H. pylori* eradication therapy for elderly patients in our hospital
Rieko Mukai
(Department of Molecular Gastroenterology and Hepatology Kyoto Prefectural University of Medicine Graduate School of Medical Science)

P14-03 *Helicobacter pylori* eradication therapies for elder patients over seventy five years by using Vonoprazan

Sasaki Hitoshi

(Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center)

P14-04 Actual condition of eradication treatment of elderly people in general hospitals

Sei Kurokawa

(Department of Internal medicine, Sapporo Doto Hospital)

Poster Session 15

Saturday, June 30th, 2018 13:40~14:10 Poster Session (2F Kuju)

Others

Chair : Tomoyuki Yada

(Kohnodai Hospital, National Center for Global Health and Medicine
Department of Gastroenterology & Hepatology)

P15-01 Survey on consciousness by questionnaire about *Helicobacter pylori* infection in company

Hiroshi Serizawa

(Department of Health Care, Hitachi Systems, Ltd.)

P15-02 Baseline factors associated with effect of acotiamide

Momoko Akashi

(Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama)

P15-03 Changes of the gastric mucosal glycosylation in *H. pylori* infection using lectin microarray analysis

Ryo Ogawa

(Department of Gastroenterology, Faculty of Medicine, Oita University)

P15-04 Neutrophil-to-lymphocyte ratio in *H.pylori*-infected patients

Takamasa Ishii

(Department of General Medicine and Emergency Care, Toho University)

P15-05 Epstein-Barr virus detection using gastric biopsy specimen after rapid urease test

Hideo Yanai

(Department of Clinical Research, National Hospital Organization Kanmon Medical Center)